Literature DB >> 3319459

5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada.

L R Sutherland1, F Martin.   

Abstract

The efficacy and safety of 4 g 5-aminosalicylic acid (5-ASA) enemas were assessed in 59 patients with ulcerative colitis involving up to 50 cm of their distal colon. Twenty-nine patients received 5-ASA and 30 received a placebo. There were 12 dropouts (five in the active and seven in the placebo group) during the study because of insufficient efficacy. After six weeks of therapy, 63% of the patients receiving the 5-ASA were considered to be "much improved" by the study physician compared to 20% patients on placebo (P less than 0.0001). A disease activity index (DAI), based upon patient symptoms and sigmoidoscopic appearance, was used to assess efficacy. Mean DAI declined 75% for patients on 5-ASA enemas and 32% for patients on placebo (P less than 0.05). The 5-ASA enemas are well tolerated and are of benefit in the treatment of ulcerative colitis confined to the distal colon.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319459     DOI: 10.1007/BF01312466

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  6 in total

1.  Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.

Authors:  J H BARON; A M CONNELL; J E LENNARD-JONES; F A JONES
Journal:  Lancet       Date:  1962-05-26       Impact factor: 79.321

2.  Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.

Authors:  M J Dew; P Hughes; A D Harries; G Williams; B K Evans; J Rhodes
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-09

3.  Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis.

Authors:  M J Dew; R E Ryder; N Evans; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

4.  Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis.

Authors:  P B McIntyre; F A Macrae; L Berghouse; J English; J E Lennard-Jones
Journal:  Gut       Date:  1985-08       Impact factor: 23.059

5.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

Authors:  A S Dissanayake; S C Truelove
Journal:  Gut       Date:  1973-12       Impact factor: 23.059

6.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

  6 in total
  13 in total

1.  Meta-analysis of the placebo response in ulcerative colitis.

Authors:  Sagar Garud; Alphonso Brown; Adam Cheifetz; Emily B Levitan; Ciaran P Kelly
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

Review 2.  Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?

Authors:  Robert Battat; Parambir S Dulai; Christopher Ma; Vipul Jairath; Brian G Feagan; William J Sandborn; Reena Khanna
Journal:  Curr Treat Options Gastroenterol       Date:  2020-01-04

3.  Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group.

Authors:  W Scheppach
Journal:  Dig Dis Sci       Date:  1996-11       Impact factor: 3.199

Review 4.  Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.

Authors:  Vipul Jairath; Guangyong Zou; Claire E Parker; John K Macdonald; Mahmoud H Mosli; Reena Khanna; Lisa M Shackelton; Margaret K Vandervoort; Turki AlAmeel; Mohammad Al Beshir; Majid AlMadi; Talal Al-Taweel; Nathan S S Atkinson; Sujata Biswas; Thomas P Chapman; Parambir S Dulai; Mark A Glaire; Daniel Hoekman; Andreas Koutsoumpas; Elizabeth Minas; Mark A Samaan; Simon Travis; Geert D'Haens; Barrett G Levesque; William J Sandborn; Brian G Feagan
Journal:  J Crohns Colitis       Date:  2016-01-07       Impact factor: 9.071

5.  S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome.

Authors:  Akiko Shiotani; Hiroaki Kusunoki; Yoshiki Kimura; Mnabu Ishii; Hiroshi Imamura; Ken-ichi Tarumi; Noriaki Manabe; Tomoari Kamada; Jiro Hata; Ken Haruma
Journal:  Dig Dis Sci       Date:  2013-04-18       Impact factor: 3.199

Review 6.  Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

7.  Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis.

Authors:  Xiaojing Zhao; Changcheng Zhou; Jingjing Ma; Yunjuan Zhu; Min Sun; Peixue Wang; Yi Zhang; Haiqin Ma; Hongjie Zhang
Journal:  Sci Rep       Date:  2017-04-25       Impact factor: 4.379

Review 8.  Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.

Authors:  Vipul Jairath; G Y Zou; Claire E Parker; John K MacDonald; Turki AlAmeel; Mohammad Al Beshir; Majid A Almadi; Talal Al-Taweel; Nathan Ss Atkinson; Sujata Biswas; Thomas Chapman; Parambir S Dulai; Mark A Glaire; Daniël R Hoekman; Andreas Koutsoumpas; Elizabeth Minas; Mahmoud H Mosli; Mark Samaan; Reena Khanna; Simon Travis; Geert D'Haens; William J Sandborn; Brian G Feagan
Journal:  Cochrane Database Syst Rev       Date:  2017-09-08

9.  Recurrence of moderate to severe ulcerative colitis after fecal microbiota transplantation treatment and the efficacy of re-FMT: a case series.

Authors:  Xiao-Fei Dang; Zhao Yin; Lin Sun; Wei-Hua Yang
Journal:  BMC Gastroenterol       Date:  2020-11-26       Impact factor: 3.067

10.  Systematic review with meta-analysis: effectiveness of hyperbaric oxygenation therapy for ulcerative colitis.

Authors:  Pingrun Chen; Yina Li; Xian Zhang; Yan Zhang
Journal:  Therap Adv Gastroenterol       Date:  2021-07-17       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.